Proteomics International Laboratories (ASX:PIQ) received a dedicated billing code from the American Medical Association for its PromarkerD diagnostic test, which identifies kidney function decline in patients with Type 2 diabetes, according to a Thursday filing with the Australian bourse.
The new code will take effect for insurance claims from Oct. 1, the filing said.
The company also submitted a pricing recommendation for the test to the Centers for Medicare and Medicaid Services (CMS), the filing added.
Preliminary pricing for the test is expected in September following a review by CMS's advisory panel, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.